DNA Script to present at the Biotech Showcase conference in San Francisco


Paris, January 5th, 2017. DNA Script, a company focused on the manufacturing of synthetic DNA using a proprietary enzymatic technology, today announced it will present at the Biotech Showcase Conference on Tuesday, January 10th at 5:15 p.m PT in San Francisco, USA. The Biotech Showcase Conference is a financial investor and strategic business partnering event focused on early stage companies in the life science field.

DNA Script manufactures synthetic DNA using a proprietary template-free enzymatic technology. The company technology leverages nature's most powerful catalysts - enzymes - to overcome current inefficiencies in synthetic DNA production, and enable affordable, rapid, high-quality and high-throughput production of synthetic biology tools, such as oligonucleotides, genes, pathways and genomes. "Our long-term goal is to render DNA and gene synthesis as simple and as affordable as DNA sequencing is today", states Thomas Ybert, President and CEO.

Created in 2014 and based in Paris, France, DNA Script develops its technology in partnership with Institut Pasteur (www.pasteur.fr/en) and Institut Pierre Gilles de Gennes (www.institut-pgg.com). The technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemicals production, improved crops as well as data storage. The company completed its first institutional funding round in May 2016 led by Sofinnova Partners (www.sofinnova.fr) and with participation of Kurma Partners (www.kurmapartners.com/en) and Idinvest Partners (www.idinvest.com/en).

About DNA Script.

DNA Script is a Paris-based company focused on the manufacturing of synthetic DNA using a proprietary template-free enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable and high-quality DNA synthesis. DNA Script leverages nature's billions of years of evolution in synthesizing DNA to enable genome scale synthesis.

Its technology has the potential to greatly accelerate the development of new therapeutics, sustainable chemicals production, improved crops as well as data storage. DNA Script develops its technology in partnership with Institut Pasteur and Institut Pierre Gilles de Gennes with the support of key investors such as Sofinnova Partners, Kurma Partners and Idinvest Partners.

www.dnascript.co

Contact
Sylvain Gariel, COO
sg@dnascript.co
+33.6.28.04.53.11
www.dnascript.co
Made on
Tilda